Abstract: The present invention provides processes for the preparation of N-alkyl morphinans without the isolation of nor-morphinan intermediates. In particular, the invention provides tandem hydrolysis/alkylation reactions for the synthesis of N-alkyl morphinans.

Abstract: The present disclosure provides extended release pharmaceutical compositions comprising an opioid and an additional active pharmaceutical ingredient, wherein the composition exhibits gastric retentive properties which are achieved by a combination of a physical property of the composition and release of the opioid, wherein upon administration to a subject, the composition has at least one pharmacokinetic parameter that differs by less than about 30% when the subject is in a fasted state as compared to a fed state.

Abstract: Provided herein are compounds useful for diagnostic imaging and/or therapeutic purposes. Each compound comprises a ligand for the chemokine receptor CXCR4, which has a binding affinity for the CXCR4 receptor, measured as IC50 in the presence of 125I-CPCR4, of 250 nM or lower. The ligand is a cyclic oligopeptide moiety having a motif B-Arg or B-(Me)Arg within the cyclic moiety, wherein B is a basic amino acid, a derivative thereof, or phenylalanine, provided that the motif is B-Arg when B is a N?-methyl derivative of a basic amino acid, and provided that the cyclic oligopeptide moiety has a sequence other than cyclo[D-Tyr-Arg-Arg-NaI-Gly] or cyclo[D-Tyr-Orn-Arg-NaI-Gly].

Abstract: A pharmaceutical product supply is disclosed in the form of a container, a pharmaceutical product receiver, pharmaceutical product, an adhesive, and at least one release liner. The pharmaceutical product receiver includes a plurality of receptacles for pharmaceutical product. The container is initially disposed in a first configuration where all of the pharmaceutical product receiver receptacles may be accessible. The container is thereafter disposable in a second configuration where no covering for any of the pharmaceutical product receiver receptacles is accessible through any openable access incorporated by the container. One or more release liners may be moved to expose adhesive for disposing and retaining the container in its second configuration. The noted second configuration of the container facilitates disposal of the pharmaceutical product supply (e.g.

Abstract: A single-use, single-patient, or patient-specific tubing set (300) is disclosed. The tubing set (300) includes at least one check valve (304), along with a use indicator (320). This use indicator (320) provides a visual indication when the tubing set (300) has been used for an injection. In this regard, a piston (340) moves from one position to another when exposed to a certain fluid pressure.

Abstract: Methods for producing stabilized solid dosage form pharmaceutical compositions are provided. In particular, methods for preparing protected granules containing morphinans, and solid dosage form pharmaceutical compositions produced using the morphinan-protected granules are provided.

Abstract: A process for the preparation of iosimenol comprising reacting 5,5?-[(1,3-dioxo-1,3-propanediyl)diimino]bis[N-(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-benzenedicarboxamide] (C-VI) with a 3-halo-1,2-propanediol in an aqueous solvent. A process for the preparation of C-VI comprising reacting 3,3?-[(1,3-dioxo-1,3-propanediyl)diimino]bis[5-(aminocarbonyl)-2,4,6-triiodobenzoyl chloride] (C-V) with 3-amino-1,2-propanediol in the presence of an inorganic base and a suitable non-aqueous polar solvent. A process for the preparation of C-V comprising reacting 3-amino-5-(aminocarbonyl)-2,4,6-triiodobenzoyl chloride (C-IV) with malonyl dichloride in a solvent comprising a suitable ester solvent, a suitable nitrile solvent or mixtures thereof.

Abstract: The present invention generally relates to nonionic x-ray contrast media formulations, radiological compositions containing such agents and methods for x-ray visualization utilizing such compositions. The invention especially relates to injectable radiological compositions for x-ray visualization comprising a pharmaceutically acceptable vehicle and a mixture of a monomer, being a triiodo-substituted benzene nucleus, and a dimer, being two linked triiodo-substituted benzene nuclei, such that the mixture demonstrates favorable properties.

Abstract: A hand-held syringe includes a handle configured for suspending and using the syringe with a single hand. The handle includes pivotally connected first and second members. The members of the handle may be pivotally connected at intermediate positions along the lengths thereof or at or near ends thereof. The first member is associated with, and may be pivotally connected to, a syringe barrel, while the second member is associated with, and may be pivotally connected to, a syringe plunger. The syringe may be configured for a single-use (i.e., it may be disposable). Applications of use and methods of using a hand-held syringe are also disclosed.

Abstract: An improved process for the N-alkylation of tertiary morphinan alkaloid bases to form the corresponding quaternary morphinan alkaloid derivatives.

Abstract: A dual head contrast media injection system performs a patency check or test injection, determining flow rate and/or flow volume from the programmed protocol. The tubing that connects syringes to a patient shares only a short common section near to the patient. Appropriate injection steps are taken to compensate for tubing elasticity. A wireless remote control and a touch screen control are provided, improving functionality and information delivery. The display brightness is controlled based on the ambient light, and the display panel includes a double swivel permitting re-orientation. The orientation of the display may also be controlled based on, e.g., the current step, the tilt angle of the powerhead, or a manual control. Furthermore, the display is customizable to identify the type of fluid (contrast, saline, etc.) on either side of the injector, to provide matched color coding, and to provide a folder/tab analogy for retrieving injection protocol parameters.

Abstract: A contrast media injection system includes detects the absolute position of the syringe ram using a non-contact sensor. A series of magnets and Hall-Effect sensors may be used or an opto-reflective system. Illuminated knobs that are connected to the drive mechanism for the syringe ram rotate with the drive and provide visual feedback on operation through the illumination. Analog Hall-Effect sensors are used to determine the presence or absence of magnets that identify the type of faceplate being used. The faceplates include control electronics, connected to the powerhead through connectors, which may be interchangeably used by the two faceplates. The faceplate electronics include detectors for automatically detecting the capacity of pre-filled syringes.

Abstract: A powered injector that stores energy at a low rate when not in use and delivers energy at a high rate during injection. Energy may be stored in a highly responsive energy storage device, such as a capacitor, for rapid delivery of power to the injector motor. In certain embodiments, wires connecting the powered injector to a power supply may be relatively small and inexpensive because the current and voltage loads placed on the wires are relatively low.

Abstract: The present disclosure provides an extended release pharmaceutical composition comprising oxycodone and acetaminophen that provides a rapid onset of analgesia, and reduced levels of acetaminophen near the end of the dosing interval. Also provided are methods for reducing the risk of acetaminophen-induced hepatic damage in a subject being treated with an acetaminophen containing composition, as well as methods for treating pain in a subject in need thereof.

Abstract: Novel azo, azide, and sulfenate photoactive compounds and methods using the compounds for photodiagnostic and/or phototherapeutic procedures. The compounds have the formula E-L-DYE-X—Y, wherein DYE is a photoactive component comprising a photoactive diagnostic agent, a photoactive type 1 agent, a photoactive type 2 agent, or a combination thereof; Y is a photoactive component comprising a photoactive type 1 agent, a photoactive type 2 agent, or a combination thereof; E is a targeting component for targeting the compound to an anatomical and/or physiological site of a patient; L is a linking component for linking E to DYE; and X is a linking component for linking DYE to Y.

Abstract: The present invention provides (+)-morphinanium compounds comprising substituted 6-hydroxy or 6-amine groups. The invention also provides methods for inhibiting microglial activation by administering the compounds of the invention.

Abstract: In one characterization, the present invention relates to a radiation-shielding assembly for holding a container having a radioactive material disposed therein. The assembly may, at least in one regard, be referred to as an elution shield and/or a dispensing shield. The assembly includes a body at least partially defining a cavity. There is at least one opening through the body into the cavity. The assembly may include a cap that at least generally hinders escape of radiation from the assembly through the opening. The cap may be releasably attached to the body in one orientation and may establish non-attached engagement with the body in another orientation. The assembly may include an adjustable spacer system for adapting the assembly for use with containers having different heights.

Abstract: A power injector syringe assembly (110) is disclosed. The power injector syringe assembly (110) includes a power injector syringe (112) and coupling (130) that are permanently joined. The coupling (130) includes a wedge-shaped mounting flange (144) to facilitate installation of the assembly (110) on a syringe mount (200) of a power injector. The coupling (130) also includes at least one coupling member (150) to facilitate removal of the assembly (110) from the syringe mount (200).

Abstract: The present invention relates to the economical and separation of benzphetamine hydrochloride and methamphetamine by liquid extraction. An extraction process employing a suitable organic solvent and water at a pH in the range of from about 6 to about 8 provides excellent removal of the methamphetamine by dissolution in the water phase while the benzphetamine dissolves in the organic phase. Simple separation of the two phases results in separation of the two amines.

Abstract: Some injectors of the invention may include a fluid drive responsive to pressure of a working fluid (e.g., liquid, pneumatic, or both) to impart a sequence of forces to drive a delivery device (e.g., a syringe) to deliver a medical fluid (e.g., a contrast agent, a radiopharmaceutical, a drug, or a combination thereof). Some injectors may include a multimedia tube configured to pass a working fluid (e.g., air) and a light signal (e.g., infrared). Some injectors may include a peristaltic drive responsive to pressure of a working fluid.